Hera BioLabs provides preclinical research services with a focus on gene editing. The company offers proprietary platforms and custom research models to support drug discovery and development.

Hera BioLabs

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Analytics

Content Delivery Network

Senior Director, Business Development/Gene Editing Solutions

Christopher Brenzel

Assistant Director of R&D and in Vivo Services

Diane Begemann

Director, in-Vitro Studies

Valeriya Adjan Steffey, M.D.

Business Management

Emily Baldwin

Engineering

Abigail Ross

Scientist, Business Development

Grace Walton

Animal Care Technician

Johanna Stanley

Lauren Keach

Research Associate

Nicolas Johnston

Razoanul Haque

Michael Schlosser

Chief Executive Office

Southern US Companies (Top 10K)

Kentucky Companies With Fewer Than 100 Employees

Biotechnology Companies (Top 10K)

Health Care Companies With Fewer Than 50 Employees (Top 10K)

Hera Testing Laboratories develops preclinical drugs for vivo and vitro toxicology. The company's line of business includes providing professional analytic and diagnostic services for the medical profession.

Venture Round - Hera Testing Laboratories

Lexington

Kentucky

United States

North America

Hera Testing Laboratories

Genetically modified rat models for severe combined immunodeficiency (scid)

A highly immunodeficient rat model used for xenograft studies, enabling the engraftment of human tissues and providing larger tumor volumes and more frequent blood collection compared to mouse models.

Custom gene editing services using technologies like piggyBac and Cas-CLOVER for creating stable cell lines, animal models, and other complex gene modifications.

In vivo oncology studies using the SRG rat and other models to test the efficacy of preclinical therapeutics, including patient-derived xenografts (PDX).

A non-viral gene editing platform for stable cell line creation, capable of integrating large DNA fragments into genomes for long-term expression.

A dimeric nuclease technology for targeted gene modifications with high efficiency and low off-target activity, used for creating custom cell lines and other applications.

Services for developing stable mammalian cell lines for bioproduction, including antibody production in CHO cells using piggyBac and Cas-CLOVER technologies.

Pakistan

Asia

India

Philippines

HTML5

Comodo PositiveSSL Certificates

jQuery

GoDaddy Premium DNS

Wordpress

Google Maps API

Adobe Flash

Google Drive

F5 NGINX

Vimeo

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 19, 2024 2:34 PM	fc102a7f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 2:34 PM	288ccaf4
crunchbase trigger	general	Nov 19, 2024 2:34 PM	e83af890
crunchbase profile	general	Nov 20, 2024 4:48 AM	d3491d9e
li profile	general	Nov 19, 2024 2:34 PM	aed73483
translate crunchbase fundingrounds	general	Nov 20, 2024 5:35 AM	b1b2701b
peers	general	Nov 19, 2024 2:34 PM	aac0fb74
news basic	general	Nov 19, 2024 2:34 PM	e3903701
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

HERA

COM:HERABIOLABS

Hera BioLabs